United Therapeutics | UTHR

Peers Price Chg Day Year Date
AMRN Amarin 0.86 -0.03 -3.03% -31.74% Apr/25
ARDX Ardelyx 6.31 -0.12 -1.87% 35.41% Apr/25
BAX Baxter International 40.25 -0.73 -1.78% -12.65% Apr/25
BAYN Bayer 27.32 0.43 1.58% -54.25% Apr/26
BIIB Biogen 202.49 0.36 0.18% -29.70% Apr/25
BMRN BioMarin Pharmaceutical 82.17 -9.07 -9.94% -11.65% Apr/25
GILD Gilead Sciences 65.07 -1.83 -2.73% -22.30% Apr/25
GSK GlaxoSmithKline 1,634.00 -6.50 -0.40% 13.71% Apr/26
HALO Halozyme Therapeutics 38.46 -0.66 -1.69% 17.04% Apr/25
INSM Insmed 24.93 -0.88 -3.41% 28.77% Apr/25
IONS Ionis Pharmaceuticals 41.81 -0.65 -1.53% 16.95% Apr/25
ITCI Intra Cellular Therapies 72.13 -0.96 -1.31% 18.17% Apr/25
JNJ J&J 146.84 -1.73 -1.16% -9.70% Apr/25
MRNA Moderna 106.22 -2.79 -2.56% -18.75% Apr/25
PFE Pfizer 25.26 -0.97 -3.69% -34.61% Apr/25
PTCT PTC Therapeutics 25.49 0.28 1.11% -51.21% Apr/25
REGN Regeneron Pharmaceuticals 906.54 -16.99 -1.87% 16.52% Apr/25
SRPT Sarepta Therapeutics 127.41 3.16 2.54% 4.20% Apr/25
TEVA Teva Pharmaceutical Industries 4,933.00 48.00 0.98% 63.07% Apr/25
UTHR United Therapeutics 235.98 -1.02 -0.43% 4.48% Apr/25
VRTX Vertex Pharmaceuticals 397.24 -3.35 -0.84% 22.87% Apr/25

Indexes Price Day Year Date
CCMP USND 15612 -100.99 -0.64% 31.70% Apr/25
MID US400 2887 -13.99 -0.48% 18.79% Apr/25

United Therapeutics traded at $235.98 this Thursday April 25th, decreasing $1.02 or 0.43 percent since the previous trading session. Looking back, over the last four weeks, United Therapeutics lost 4.79 percent. Over the last 12 months, its price rose by 4.48 percent. Looking ahead, we forecast United Therapeutics to be priced at 225.33 by the end of this quarter and at 212.67 in one year, according to Trading Economics global macro models projections and analysts expectations.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. The Company market and sell four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution, which includes the Tyvaso Inhalation System; Orenitram (treprostinil) Extended-Release Tablets; and Adcirca (tadalafil) Tablets. In the United States, the Company also markets and sells an oncology product, Unituxin (dinutuximab) Injection, which is approved for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion.